Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycobacterium w in Critically Ill COVID-19 Patients
NCT04347174Phase 2Completed
- Sponsor
- Cadila Pharmaceuticals
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MYCIDAC-C in coronavirus disease 2019 (COVID-19), sponsored by Cadila Pharmaceuticals. Started Apr 2020; status: completed.
02
Drugs
MYCIDAC-C
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04347174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347174.